Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
A Gala Tribute to Global Copycats

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

Improving, developing and integrating your e-Clinical Systems...

20 Mar 07

Covering all the major topics surrounding EDC and other e-Clinical technologies, this year’s e-Clinical Trials event will also look carefully at how to integrate a range of systems for a successful e-Clinical programme and bring you up-to-date on current standards and the latest technological options. Delegates will also benefit from a highly detailed interactive workshop on managing e-Clinical Trials in exotic and difficult locations. Furthermore, This year’s e-Clinical Trials conference wil
Amir Sebahat

Global Image Re-Positioning 2007

30 Jan 07

Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
Naseem Javed

Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy

30 Jan 07

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen

The iPhones, iPains & iProblems

16 Jan 07

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
Naseem Javed

Eltrombopag (Promacta) offers hope of an effective oral treatment for bleeding due to thrombocytopenia

03 Jan 07

Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III
Olwen Glynn Owen

Pharma turns to reformulation to maximize ROI

15 Dec 06

With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
Datamonitor

Patient Adherence: The Transformation of Loyalty Strategies

12 Dec 06

Frost & Sullivan, along with their panel of distinguished industry experts, will take a look at the changing dynamics in today's U.S. pharmaceutical industry. The panel will review traditional adherence programs, examine what is and is not working, and what the next steps are toward addressing the multiple barriers contributing to non-adherence. For additional information, please visit http://ebroadcast.frost.com/loyalty
Brian Denker

Antihypertensives: Generics striking at heart of the market

08 Dec 06

Despite almost 200 million people suffering from high blood pressure in the western world alone, the growth rate of the antihypertensive market is actually slowing, largely as a result of generic incursion. In fact many pharmaceutical companies, including those with strong cardiovascular portfolios, are turning their back on this market in favor of more profitable indications, such as oncology.
Datamonitor

AstraZeneca has announced that it will launch a generic version of its own heart drug Toprol XL.

24 Nov 06

AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.